Side-by-side · Research reference

HCGvsHGH 191AA

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED12/52 cited

BFDA-ApprovedHUMAN-REVIEWED0/75 cited

HCG

Glycoprotein Hormone · LH Mimetic

2,000 IUTypical dose (2×/wk)Konsam 2026 Zachariou 2026

70–90%Sperm induction rateHuijben 2026 Zachariou 2026

12–24 moTime to sperm appearanceHuijben 2026 Nariyoshi 2025

IM or SQ · 2–3×/week

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

01Mechanism of Action

Parameter

HCG

HGH 191AA

Primary target

LH receptors on testicular Leydig cellsSchröder-Lange 2025

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

Pathway

hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Downstream effect

Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026 Zachariou 2026

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Feedback intact?

No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

Origin

Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Antibody development

Rare with recombinant; possible with urinary-derived formulations

Rare — <2% develop binding antibodies, typically non-neutralizing

02Dosage Protocols

Parameter

HCG

HGH 191AA

Hypogonadotropic hypogonadism (monotherapy)

2,000 IU IM/SQ 2–3×/weekKonsam 2026 Zachariou 2026

Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.

—

Combined therapy (hCG + FSH)

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026 Nariyoshi 2025

Preferred for azoospermia; FSH added after initial hCG phase or from outset.

—

Triple therapy (experimental)

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026

May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).

—

Cryptorchidism (pediatric)

500–4,000 IU IM 2–3×/week for 3–6 weeks

—

Evidence basis

RCT / Meta-analysis / FDA-approvedKonsam 2026 Huijben 2026

FDA-approved / decades of RCT data

Duration to sperm appearance

12–24 months (median ~18 mo)Huijben 2026 Zachariou 2026

Congenital HH may require longer treatment; acquired HH responds faster.

—

Route

Intramuscular or subcutaneousKonsam 2026

—

Monitoring

Serum testosterone, semen analysis q3–6mo, testicular ultrasound

Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025

IGF-1, glucose, thyroid function, bone age (children)

Pediatric GHD

—

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

Adult GHD

—

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

Turner syndrome

—

0.045–0.050 mg/kg/day SQ

Idiopathic short stature

—

0.037 mg/kg/day SQ

AIDS wasting

—

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

Frequency

—

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Duration

—

Years (children until epiphyseal closure); indefinite (adult GHD)

03Metabolic / Fat Loss Evidence

Parameter

HCG

HGH 191AA

Primary fat target

—

Visceral and subcutaneous adipose tissue

Mechanism

—

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

Effect on lean mass

—

Significant lean mass increase (protein synthesis, nitrogen retention)

Insulin sensitivity

—

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

IGF-1 elevation

—

Dose-dependent, significant — primary anabolic mediator

Glucose metabolism

—

Hyperglycemia risk, especially high doses (AIDS wasting)

Body composition

—

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

Clinical context

—

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

04Side Effects & Safety

Parameter

HCG

HGH 191AA

Injection site reaction

Pain, erythema (mild, transient)

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

Gynecomastia

Aromatization of elevated testosterone to estradiol; dose-dependent

Adolescent males (physiological during puberty, may be exacerbated)

Testicular discomfort / Edema

Rapid testicular growth in hypogonadal males; usually self-limiting

—

Polycythemia

Elevated hematocrit from supraphysiological testosterone; monitor CBC

—

Mood / Libido changes

Variable; usually positive with normalization of testosterone

—

Acne / Oily skin

Androgen-mediated; dose-dependent

—

Prostate concerns

Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)

—

Antibody formation

Rare with recombinant; possible with urinary-derived

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

Fluid retention / Edema

—

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

Glucose intolerance

—

Hyperglycemia, new-onset diabetes (anti-insulin effect)

Intracranial hypertension

—

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

Slipped capital femoral epiphysis

—

SCFE risk in children — limp, hip/knee pain (requires surgery)

Scoliosis progression

—

Rapid growth may unmask/progress scoliosis (monitor spine in children)

Hypothyroidism

—

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

Cancer risk

—

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

Pancreatitis

—

Rare. Higher risk in children with certain syndromes (Prader-Willi).

Absolute Contraindications

HCG

·Androgen-dependent malignancy (prostate, breast cancer)
·Hypersensitivity to hCG or excipients
·Precocious puberty

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Relative Contraindications

HCG

·Untreated obstructive sleep apnea
·Severe cardiovascular disease (polycythemia risk)
·History of thromboembolism

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

05Administration Protocol

Parameter

HCG

HGH 191AA

1. Reconstitution (if lyophilized)

Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

2. Injection site

Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

3. Timing

Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

5. Needle selection

IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

6. Monitoring

—

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

06Stack Synergy

HCG

— no documented stacks

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms